BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9201921)

  • 1. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
    Barnard J; Borkow G; Parniak MA
    Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
    Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
    Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA
    Biochemistry; 1995 Apr; 34(13):4346-53. PubMed ID: 7535561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
    Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
    J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
    Currens MJ; Mariner JM; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
    Borkow G; Arion D; Wainberg MA; Parniak MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
    Pelemans H; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    Hossain MM; Parniak MA
    J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamide.
    Herschhorn A; Oz-Gleenberg I; Hizi A
    Biochemistry; 2008 Jan; 47(1):490-502. PubMed ID: 18052256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
    Ren J; Esnouf RM; Hopkins AL; Warren J; Balzarini J; Stuart DI; Stammers DK
    Biochemistry; 1998 Oct; 37(41):14394-403. PubMed ID: 9772165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate.
    Wöhrl BM; Krebs R; Goody RS; Restle T
    J Mol Biol; 1999 Sep; 292(2):333-44. PubMed ID: 10493879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
    Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
    Treesuwan W; Hannongbua S
    J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.
    Quiñones-Mateu ME; Soriano V; Domingo E; Menéndez-Arias L
    Virology; 1997 Sep; 236(2):364-73. PubMed ID: 9325244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.
    Borkow G; Salomon H; Wainberg MA; Parniak MA
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):711-4. PubMed ID: 12167278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
    Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
    J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.